We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

New Treatment for COVID-19 Using Ethanol Vapor Inhalation .

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04554433
Recruitment Status : Unknown
Verified October 2020 by Ragab, Mansoura University.
Recruitment status was:  Not yet recruiting
First Posted : September 18, 2020
Last Update Posted : October 28, 2020
Information provided by (Responsible Party):
Ragab, Mansoura University

Brief Summary:

Since ARDS is a major complication of COVID - 19 with subsequent formation of non-cardiogenic pulmonary edema , worsening the oxygenation of the patients and foamy and even bloody sputum formation, so the idea is to use alcohol inhalation as it reduce surface tension on the alveoli and markedly decrease sputum formation with improvement on oxygenation beside its cytolethal effect on virus lipid bilayer.

A lot of researches and publications proved the role of alcohol inhalation in treatment of pulmonary edema. Alcohol inhalation may has inflammatory effect and dangerous effect on patients but this can be controlled by the actual concentration used and the way we use it according to general condition of the patient and with the help of anti - inflammatory action of Asprin .

Condition or disease Intervention/treatment Phase
Covid-19 Drug Effect Drug: Ethanol with Asprin Phase 3

Detailed Description:

Corona viruses can cause diseases in both animals and humans. Many of them typically infect upper respiratory tract with minor symptoms. However, three corona viruses can infect lower respiratory tract and cause fatal pneumonia; which are severe acute respiratory syndrome corona virus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and ( SARS-CoV-2). SARS-CoV-2 shares 78% similarity of genetic material with SARS-CoV.

Pathophysiology of both viruses are closely similar, with destructive inflammatory response resulting in airway damage. That's why, disease severity in patients depends, not only on the viral infection, but also on the host response.

In many cases, this will resolve the infection. However, in other cases, immune response dysfunctions and causes severe lung and systemic pathology ending to ARDS and respiratory failure .

Treatment according to this protocol will be focused on using Asprin to decrease inflammatory reaction weather from the virus or after using alcohol.

Alcohol will be used by different methods and concentration in order to decrease surface tension on alveoli , decreasing foamy sputum secretion , increasing vascular permeability and improving oxygenation .

Also the investigator will use it as a prophylaxis for health care workers to disinfect the virus as soon as possible while it is present in nasal mucosa and upper airway.

Patients will be classified according to inclusion and exclusion criteria and will be divided into groups and they will receive the protocol as it is designed in concentrations and techniques suitable for their medical condition .

In this trial , The investigator will use 4 method to administrate Ethyl Alcohol to the patient by different concentrations .

  1. Inhaling alcohol vapor through nostrils .
  2. Inhalation of Alcohol vapor driven by Oxygen .
  3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.
  4. Ethyl Alcohol infusion into the airway . In each method , the patient will be prepared for one day before starting the protocol by prophylactic antibiotic , anti - inflammatory , mucolytic and bronchodilators .

Investigations will be made before starting for follow up of the results .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
  • (A) group: will receive the new protocol .
  • (B) group: Will receive the standard protocol .
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Disinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin .
Estimated Study Start Date : December 1, 2020
Estimated Primary Completion Date : October 1, 2021
Estimated Study Completion Date : June 1, 2022

Arm Intervention/treatment
Active Comparator: Intervention
A ) Treatment group will receive a combination of Asprin in anti - inflammatory dose and controlled ethanol vapor inhalation in concentraions and technique according to their medical condition .
Drug: Ethanol with Asprin

Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .

  1. Inhaling alcohol vapor through nostrils .
  2. Inhalation of Alcohol vapor driven by Oxygen .
  3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.
  4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .

Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results .

Other Name: Controlled ethanol vapor inhalation combined with oral Asprin .

No Intervention: Control
B ) Control group : will receive the standard protocol . Data collection will include : sociodemographic data , clinical history , results of follow up ( daily or according to clinical situation ) Follow up : to record any side effects of drugs , and swab will be taken for PCR .

Primary Outcome Measures :
  1. Disinfection of COVID-19 in human respiratory tract . [ Time Frame: Negative PCR test within 7 days from starting the protocol . ]
    Destruction of COVID-19 in human respiratory tract and treatment of the patients with COVID 19 and Negative PCR test .

Secondary Outcome Measures :
  1. Improvement of general condition of mechanically ventilated patients confirmed COVID-19 positive .. [ Time Frame: Negative PCR test within 10 days from starting the protocol . ]
    Decrease mortality rate of mechanically ventilated patients with COVID-19 . Protection of health care workers . Negative PCR test .

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age from 20 - 60
  • Confirmed COVID-19 positive with PCR test .
  • Admitted to Mansoura university quarantine hospital ..
  • Fever ≥ 38
  • Respiratory rate ≥ 20
  • Myalgia , Arthralgia and Sore throat .
  • Radiological findings consisting with COVID-19 .
  • Welling to participate and able to give fully informed consent. Specific inclusion criteria according to the concentration and method :-

    • Inhalation of Alcohol vapor driven by Oxygen Respiratory distress ( Dyspnea - Orthopnea ) Spo2 : 65 - 85 ABG : Respiratory Alkalosis due to dyspnea and tachypnea PaO2 / FIO2 ratio > 300 mmHg under the condition in the hospital room (Moderate illness).
    • Inhalation of Alcohol vapor driven by oxygen in case of ARDS. Respiratory failure . CT : lobar collapse and nodules Non cardiogenic pulmonary edema excluded by ECHO or signs of overload . PaO2 / FIO2 ratio 101 - 300 mmHg on CPAP or Vent . ( Mild to moderate ARDS)
    • Ethyl Alcohol infusion into the airway PaO2 / FIO2 ratio ≤ 100 mmHg ( Sever ARDS )

Exclusion Criteria:

  • Absence of any item from inclusion criteria
  • Pregnancy .
  • Signs of dehydration , Sepsis or shortness of breathing.
  • Asthmatic patients .
  • COPD .
  • Smokers ≥ 10 years .
  • Hypersensitivity to Alcohol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04554433

Layout table for location contacts
Contact: Ragab +201099323347 Dr.ezz2712@gmail.com

Sponsors and Collaborators
Mansoura University
Layout table for additonal information
Responsible Party: Ragab, Resident of anesthesia and surgical ICU, Mansoura University
ClinicalTrials.gov Identifier: NCT04554433    
Other Study ID Numbers: 20.08.79
First Posted: September 18, 2020    Key Record Dates
Last Update Posted: October 28, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ragab, Mansoura University:
Clinical trial
Ethyl alcohol vapor inhalation
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Aspiration
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Pathologic Processes
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs